Dalpiciclib combined with endocrine therapy and concomitant radiotherapy in early-stage HR+/HER2– breast cancer: A phase II study
European Journal of Cancer · 2026-03 · 237 · 116421
DOI: 10.1016/j.ejca.2026.116421 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2026-03. Verfasst von Y. Wang und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Wang, Y., Qin, M., Guochen, Z., Guohui, H., Lixin, D., Yafen, Z., & Xiangyang, G. (2026). Dalpiciclib combined with endocrine therapy and concomitant radiotherapy in early-stage HR+/HER2– breast cancer: A phase II study. European Journal of Cancer, 237, 116421. https://doi.org/10.1016/j.ejca.2026.116421
Vancouver
Wang Y, Qin M, Guochen Z, Guohui H, Lixin D, Yafen Z, et al. Dalpiciclib combined with endocrine therapy and concomitant radiotherapy in early-stage HR+/HER2– breast cancer: A phase II study. European Journal of Cancer. 2026;237:116421. doi:10.1016/j.ejca.2026.116421
BibTeX
@article{Wang2026,
author = {Wang, Y. and Qin, M. and Guochen, Z. and Guohui, H. and Lixin, D. and Yafen, Z. and Xiangyang, G.},
title = {Dalpiciclib combined with endocrine therapy and concomitant radiotherapy in early-stage HR+/HER2– breast cancer: A phase II study},
journal = {European Journal of Cancer},
year = {2026},
volume = {237},
pages = {116421},
doi = {10.1016/j.ejca.2026.116421}
}
EUVIMED